## 3 Results  
S Sixty-five patients with periodontitis were divided into group I with 35 cases, mean aged 50.4 \(\pm\) 10.6 years old (limits: 34-67 years), and group II with 30 controls, mean aged 44 \(\pm\) 19 years old (limits: 25-81 years). No statistically significant difference was found between the age of subjects from the two groups (t = 1.321, df = 28.35, \(p\) = 0.197).  
The distribution by age and gender revealed a similar mean age of males and females in the group of cases and younger females in the control group (Table 1).  
Figure 1: Flow chart with study group characteristics.  
For group I (test), no statistically significant difference was noted among the mean age group of males and females (t = 0.589, df = 23, \(p\) = 0.561). For group II (control), statistically significant differences were noted among the mean age group of males and females (t = \(-\)8.219, df = 18, \(p\) < 0.001) ([PERSON]'s test for equality of variances).  
After finishing the administration of all 10 Alflutop vials and SRP, respectively, all patients were examined, and the final measurements were compared with the initial ones. No side effects of Alflutop were reported, even pain at the infiltration sites.  
The Gingival Index (GI), measured before and after therapy in both groups and analyzed using a two-proportion z-test, noticed no statistically significant differences for score 0 (normal aspect) registered in more than a half of cases and controls (n I = 14; 56% vs. n II = 13; 65%; \(p\) = 0.540), and score 1 (mild inflammation and no bleeding) was 2 times greater in cases (n I = 11; 44% vs. n II = 4; 20%; \(p\) = 0.090). Statistically significant differences were recorded between cases with a score of 2 of the GI (moderate inflammation, bleeding on probing) after Alflutop, who presented a statistically significant reduction of GI score to 1 or even zero after therapy (\(p\) = 0.045) compared to controls (Figure 2).  
The PBI score of 1 underwent a statistically significant reduction in the Alflutop group vs. the SRP groups (\(p\) = 0.045) (Figure 3).  
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Group** & **Sex** & **N** & **Minimum** & **Maximum** & **Mean** & **Std. Deviation** \\ \hline \multirow{2}{*}{Alflutop} & Female/Age & 19 & 40 & 67 & 51.57 & 8.31 \\ \cline{2-7}  & Male/Age & 16 & 34 & 64 & 49 & 13.42 \\ \hline \multirow{2}{*}{Control} & Female/Age & 19 & 25 & 46 & 33.36 & 8.88 \\ \cline{2-7}  & Male/Age & 11 & 50 & 81 & 69.33 & 9.20 \\ \hline \hline \end{tabular}
\end{table}
Table 1: Age (mean) by group and by sex of the final study groups.  
Figure 2: Evolution of Gingival Index in cases compared to controls (percentage of cases exhibiting GI reduction in both control and test group).  
A statistically significant reduction in pathologic tooth mobility was observed in patients from group I, compared to the control group, for cases with first-degree tooth mobility (\(p=0.02\)), as well as for lesions exhibiting second-degree tooth mobility (\(p=0.045\)) (Figure 4).  
Maximum PD significantly reduced in both groups when comparing initial and final measurements (before and after therapy) (\(p=0.001\)), but the reduction rate was not statistically significant among cases vs. controls (\(p=0.356\)).